Funding
Two public German venture funds, High-Tech Gründerfonds and Bayern Kapital, are investing €400,000 in Chromotek GmbH, to fund research and development work leading up to the market launch of the company’s chromobody technology for use in living cell analysis.
Chromotek GmbH, a spin-out from the Ludwig Maximilian University in Munich, develops and distributes chromobody technology-based research reagents that can be used to isolate and screen for cellular components in proteomics research.
Bernd Goergen, Senior Investment Manager at High-Tech Gründerfonds, said, “With our investment we are funding not only highly innovative technology in the growth sector of high-content screening, but also an exceptionally dynamic start-up team that has profound market knowledge and commercialisation expertise.”
Chromobodies are a new kind of fluorescent nanoprobe that are extremely small, very stable, and economical to produce. In contrast to conventional antibodies, chromobodies are suited to real-time screening in living cells and are therefore useful for high-content analysis.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
